{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T16:07:08Z","timestamp":1781626028840,"version":"3.54.5"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T00:00:00Z","timestamp":1781568000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T00:00:00Z","timestamp":1781568000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Can J Public Health"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>As Canada contends with rising healthcare costs and health system strain, vaccination programs stand out as stabilizing health infrastructure. Vaccination can reduce the burden of avoidable illness and dampen volatility arising from seasonal disease surges and outbreaks. Together, these effects can preserve clinical and public health capacity, improve fiscal predictability, and support health system resilience. These system-level benefits are generally not fully captured by conventional cost-utility analyses. Drawing on Canadian evidence, we outline how vaccination programs stabilize healthcare use and spending, and how a stabilization lens complements conventional economic evaluation. Recognizing vaccines as cost-stabilizing infrastructure may influence how vaccination programs are prioritized, budgeted, and evaluated in health system planning.<\/jats:p>","DOI":"10.17269\/s41997-026-01222-w","type":"journal-article","created":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T15:20:00Z","timestamp":1781623200000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Vaccination as cost-stabilizing health infrastructure: A Canadian perspective"],"prefix":"10.17269","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4373-9337","authenticated-orcid":false,"given":"Ashleigh R.","family":"Tuite","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5009-6926","authenticated-orcid":false,"given":"David N.","family":"Fisman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9974-8016","authenticated-orcid":false,"given":"Ellen","family":"Rafferty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2092-9143","authenticated-orcid":false,"given":"Matthew","family":"Tunis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,16]]},"reference":[{"key":"1222_CR1","volume-title":"Medical surge capacity and capability: A management system for integrating medical and health resources during large-scale emergencies","author":"JA Barbera","year":"2007","unstructured":"Barbera, J. A., Macintyre, A. G., Knebel, A., & Trabert, E. (2007). Medical surge capacity and capability: A management system for integrating medical and health resources during large-scale emergencies (2nd ed.). U.S. Department of Health and Human Services.","edition":"2nd ed."},{"key":"1222_CR2","unstructured":"Canadian Institute for Health Information. (2023). Commonwealth Fund survey, 2023. https:\/\/www.cihi.ca\/en\/commonwealth-fund-survey-2023"},{"key":"1222_CR3","unstructured":"Canadian Institute for Health Information. (2024a). National health expenditure trends, 2024: Data tables \u2014 Series C."},{"key":"1222_CR4","unstructured":"Canadian Institute for Health Information. (2024b). National health expenditure trends, 2024 \u2014 Snapshot. https:\/\/www.cihi.ca\/en\/national-health-expenditure-trends-2024-snapshot"},{"issue":"47","key":"1222_CR5","doi-asserted-by":"publisher","first-page":"E1619","DOI":"10.1503\/cmaj.1096028","volume":"194","author":"D Duong","year":"2022","unstructured":"Duong, D. (2022). Calls for masking in schools as respiratory infections overwhelm children\u2019s hospitals. Canadian Medical Association Journal, 194(47), E1619\u2013E1620.","journal-title":"Canadian Medical Association Journal"},{"key":"1222_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.lana.2025.101143","author":"AA Grima","year":"2025","unstructured":"Grima, A. A., Lee, C. E., Tuite, A. R., Wilson, N. J., Simmons, A. E., & Fisman, D. N. (2025). Derivation and validation of a point-based forecasting tool for SARS-CoV-2 critical care occupancy: A population-based modeling study. The Lancet Regional Health \u2013 Americas. https:\/\/doi.org\/10.1016\/j.lana.2025.101143","journal-title":"The Lancet Regional Health \u2013 Americas"},{"key":"1222_CR7","unstructured":"National Advisory Committee on Immunization. (2023). Guidelines for the economic evaluation of vaccination programs in Canada. Public Health Agency of Canada."},{"key":"1222_CR8","volume-title":"Cost-effectiveness in health and medicine","year":"2016","unstructured":"Neumann, P. J., Ganiats, T. G., Russell, L. B., Sanders, G. D., & Siegel, J. E. (Eds.). (2016). Cost-effectiveness in health and medicine (2nd ed.). Oxford University Press.","edition":"2nd ed."},{"key":"1222_CR9","unstructured":"Organisation for Economic Co-operation and Development. (2025). Health system resilience. https:\/\/www.oecd.org\/en\/topics\/health-system-resilience.html"},{"key":"1222_CR10","unstructured":"Public Health Agency of Canada. (2022). Vaccine preventable disease surveillance report to December 31, 2019. https:\/\/www.canada.ca\/en\/public-health\/services\/publications\/healthy-living\/vaccine-preventable-disease-surveillance-report-2019.html"},{"key":"1222_CR11","unstructured":"Public Health Agency of Canada. (2023). Vaccine supply. https:\/\/www.canada.ca\/en\/public-health\/services\/vaccine-supply.html"},{"key":"1222_CR12","unstructured":"Public Health Agency of Canada. (2025). Statement from the Public Health Agency of Canada on Canada\u2019s measles elimination status. https:\/\/www.canada.ca\/en\/public-health\/news\/2025\/11\/statement-from-the-public-health-agency-of-canada-on-canadas-measles-elimination-status.html"},{"key":"1222_CR13","doi-asserted-by":"crossref","unstructured":"Ramsay, L. C., Crowcroft, N. S., Thomas, S., Aruffo, E., Teslya, A., Heffernan, J. M., Gournis, E., Hiebert, J., Jaeger, V., Jiaravuthisan, M., Sharron, J., Severini, A., Deeks, S. L., Gubbay, J., Mazzulli, T., & Sander, B. (2019). Cost-effectiveness of measles control during elimination in Ontario, Canada, 2015. Eurosurveillance, 24(11).","DOI":"10.2807\/1560-7917.ES.2019.24.11.1800370"},{"issue":"6","key":"1222_CR14","doi-asserted-by":"publisher","first-page":"263","DOI":"10.14745\/ccdr.v49i06a03","volume":"49","author":"AR Tuite","year":"2023","unstructured":"Tuite, A. R., Ng, V., Ximenes, R., Diener, A., Rafferty, E., Ogden, N. H., & Tunis, M. (2023). Quantifying the economic gains associated with COVID-19 vaccination in the Canadian population: A cost-benefit analysis. Canada Communicable Disease Report, 49(6), 263\u2013273.","journal-title":"Canada Communicable Disease Report"},{"issue":"3","key":"1222_CR15","doi-asserted-by":"publisher","first-page":"56","DOI":"10.14745\/ccdr.v52i03a01","volume":"52","author":"M Tunis","year":"2026","unstructured":"Tunis, M., Harrison, R., Ramotar, K., Tuite, A., Jensen, C., Wilkinson, K., Young, K., Zafack, J., Salvadori, M., Stevens, A., Dubey, V., & Henry, E. (2026). Canada\u2019s National Advisory Committee on Immunization (NACI) in 2025: Celebrating 60 years of service, a decade of change, and a dynamic future ahead. Canada Communicable Disease Report, 52(3), 56\u201366.","journal-title":"Canada Communicable Disease Report"},{"issue":"2","key":"1222_CR16","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s40121-020-00294-6","volume":"9","author":"MR Wilson","year":"2020","unstructured":"Wilson, M. R., Wasserman, M. D., Breton, M. C., Peloquin, F., Earnshaw, S. R., McDade, C., Sings, H. L., & Farkouh, R. A. (2020). Health and economic impact of routine pediatric pneumococcal immunization programs in Canada: A retrospective analysis. Infectious Diseases and Therapy, 9(2), 341\u2013353.","journal-title":"Infectious Diseases and Therapy"},{"issue":"5","key":"1222_CR17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0154340","volume":"11","author":"SE Wilson","year":"2016","unstructured":"Wilson, S. E., Rosella, L. C., Wang, J., Le Saux, N., Crowcroft, N. S., Harris, T., Bolotin, S., & Deeks, S. L. (2016). Population-level impact of Ontario\u2019s infant rotavirus immunization program: Evidence of direct and indirect effects. PLoS ONE, 11(5).","journal-title":"PLoS ONE"}],"container-title":["Canadian Journal of Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.17269\/s41997-026-01222-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.17269\/s41997-026-01222-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.17269\/s41997-026-01222-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T15:20:16Z","timestamp":1781623216000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.17269\/s41997-026-01222-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,16]]},"references-count":17,"alternative-id":["1222"],"URL":"https:\/\/doi.org\/10.17269\/s41997-026-01222-w","relation":{},"ISSN":["0008-4263","1920-7476"],"issn-type":[{"value":"0008-4263","type":"print"},{"value":"1920-7476","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,16]]},"assertion":[{"value":"20 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Fisman has served on advisory boards for Seqirus and Pfizer. All other authors have none to declare.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}